Latest news with #AlokDalal
Business Insider
2 days ago
- Business
- Business Insider
Jefferies Sticks to Their Sell Rating for Alkem Laboratories Ltd. (ALKEM)
Jefferies analyst Alok Dalal maintained a Sell rating on Alkem Laboratories Ltd. (ALKEM – Research Report) on May 30 and set a price target of INR4,460.00. The company's shares closed last Friday at INR5,098.50. Confident Investing Starts Here: According to TipRanks, Dalal is a 2-star analyst with an average return of 2.0% and a 50.00% success rate. Dalal covers the Healthcare sector, focusing on stocks such as Ajanta Pharma Limited, Alkem Laboratories Ltd., and Cipla Ltd. Currently, the analyst consensus on Alkem Laboratories Ltd. is a Moderate Sell with an average price target of INR4,947.50. Based on Alkem Laboratories Ltd.'s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of INR30.32 billion and a net profit of INR5.45 billion. In comparison, last year the company earned a revenue of INR29.68 billion and had a net profit of INR2.87 billion
Business Insider
3 days ago
- Business
- Business Insider
Concord Biotech Ltd. (CONCORDBIO) Receives a Hold from Jefferies
Jefferies analyst Alok Dalal maintained a Hold rating on Concord Biotech Ltd. (CONCORDBIO – Research Report) today and set a price target of INR1,700.00. The company's shares closed yesterday at INR1,748.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Dalal covers the Healthcare sector, focusing on stocks such as Ajanta Pharma Limited, Cipla Ltd, and Concord Biotech Ltd.. According to TipRanks, Dalal has an average return of 2.2% and a 55.17% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Concord Biotech Ltd..
Business Insider
25-05-2025
- Business
- Business Insider
Jefferies Reaffirms Their Buy Rating on Mankind Pharma Ltd. (MANKIND)
Jefferies analyst Alok Dalal maintained a Buy rating on Mankind Pharma Ltd. (MANKIND – Research Report) on May 23 and set a price target of INR2,870.00. The company's shares closed last Friday at INR2,425.00. Confident Investing Starts Here: According to TipRanks, Dalal is ranked #4967 out of 9536 analysts. In addition to Jefferies, Mankind Pharma Ltd. also received a Buy from J.P. Morgan's Bansi Desai in a report issued on May 21. However, on the same day, Bank of America Securities maintained a Sell rating on Mankind Pharma Ltd. (NSE: MANKIND).
Business Insider
25-05-2025
- Business
- Business Insider
Jefferies Remains a Buy on Emcure Pharmaceuticals Limited (EMCURE)
In a report released on May 23, Alok Dalal from Jefferies maintained a Buy rating on Emcure Pharmaceuticals Limited (EMCURE – Research Report), with a price target of INR1,400.00. The company's shares closed last Friday at INR1,288.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Dalal is ranked #4967 out of 9536 analysts. The analyst consensus on Emcure Pharmaceuticals Limited is currently a Hold rating. The company has a one-year high of INR1,577.50 and a one-year low of INR890.00. Currently, Emcure Pharmaceuticals Limited has an average volume of 29.65K.
